

Aim: To standardize surgical antibiotic prophylaxis.

RECOMMENDATIONS FOR SURGICAL ANTIBIOTIC PROPHYLAXIS

This guideline is intended to provide practitioners with a standardized approach to surgical prophylaxis that is safe and effective. Recommended antibiotics target anticipated organisms. A thorough clinical assessment is required to identify complicating factors that may necessitate alternative/additional therapy.

Timing of Prophylaxis:

- **Pre-Op dosing:** To be initiated within 60 minutes before surgical incision (120 minutes for vancomycin or fluoroquinolones). The goal of this timing is to ensure adequate antimicrobial tissue concentrations at the time of incision.
- **Intra-Op dosing:** To be administered if the duration of the procedure exceeds 2 half-lives of the antimicrobial agent or if there is excessive blood loss (> 20 mL/kg in pediatric patients; > 1,500 mL in adults). The goal is to maintain adequate antimicrobial concentrations throughout the surgical procedure. Intra-op redosing interval should be measured from the time of administration of the pre-op dose, not from the beginning of the procedure.
- **Post-Op dosing:** The duration of prophylaxis should be ≤ 24 hours for most procedures. Use of antibiotics beyond the recommended post-operative duration requires appropriate documentation of infection or suspected infection.

Note: According to the Infectious Diseases Society of America (IDSA), patients receiving therapeutic antimicrobials prior to surgery should also be given antimicrobial prophylaxis before surgery to ensure adequate serum and tissue levels of antimicrobials with activity against likely pathogens for the duration of the operation. For these patients, the surgeon will determine if the scheduled antibiotics are appropriate for surgical prophylaxis and if additional perioperative antibiotics or doses are needed. Administration of perioperative doses of gentamicin or vancomycin **in addition to** scheduled doses increases the risk of toxicity. Administration of perioperative doses of penicillins (e.g., ampicillin-sulbactam) or cephalosporins (e.g., cefazolin) **in addition to** scheduled doses is generally considered safe.

Drains:

According to the CDC Guideline for the Prevention of Surgical Site Infection, in clean and clean-contaminated procedures, additional prophylactic antimicrobial agent doses should not be administered after the surgical incision is closed in the operating room, even in the presence of a drain (strong recommendation; high-quality evidence).

Chest Tubes:

There is no evidence to support continuing antibiotic prophylaxis until chest and mediastinal drainage tubes are removed.

Allergy:

Beta-lactam antibiotics (e.g., cefazolin, ceftriaxone, ampicillin-sulbactam) are the safest and most effective agents for surgical prophylaxis. Use of second line agents (e.g., fluoroquinolones, vancomycin, clindamycin) are associated with inferior patient outcomes and increased risk of toxicity, *C. difficile* infection and drug-resistant organisms. Every effort should be made to thoroughly evaluate reported beta-lactam antibiotic allergies prior to surgery to ensure patients do not receive second-line, inferior agents unnecessarily. Beta-lactam allergies comprise a spectrum of allergic reactions. **See Appendix A (pages 15-18) for antibiotic choices appropriate to the type and severity of beta-lactam allergy. Cefazolin or other cephalosporins may still be indicated.**

MRSA Colonization or history of MRSA Infection:

- Clindamycin can be used instead of vancomycin if the isolate is known to be susceptible to clindamycin.
- The combination of cefazolin plus vancomycin is preferred over vancomycin alone for effective concurrent coverage of MSSA (cefazolin). Surgical prophylaxis with vancomycin alone has been associated with higher rates of MSSA surgical site infections than cefazolin alone.

Aim: To standardize surgical antibiotic prophylaxis.

Table of Contents and Quick Links to Procedure Types within Document

Cardiac Procedures	Ophthalmic	Gynecological	Vascular
Urological Procedures	Oral and Maxillofacial Surgery	Orthopedic Trauma	Fetal Surgery
Neurosurgical Procedures <ul style="list-style-type: none"> Spinal procedures without hardware implantation Spinal procedures with hardware implantation Cranial procedures 	ENT <ul style="list-style-type: none"> Otic/Ear Facial Nasal Sinus Oropharyngeal Cervical/Neck Craniofacial Reconstruction 	Plastic Surgery	General Surgery <ul style="list-style-type: none"> Thoracic Biliary tract Gastroduodenal Small intestine and colorectal Appendectomy
Perioperative Dosing of Prophylactic Antibiotics in Neonates (PMA < 44 weeks)		Perioperative Dosing for Prophylactic Antibiotics in Pediatric (PMA > 44 weeks) and Adults	
Appendix A: Beta-Lactam Allergy Guidance (can also be accessed directly from Header of "Severe β-lactam Allergy" on each page)			

TABLE 1. RECOMMENDATIONS FOR PERIOPERATIVE ANTIBIOTIC SELECTION

Type of Procedure	Recommended Agent(s)	Severe β-lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
Cardiac					
<ul style="list-style-type: none"> Congenital heart surgery Valve repair Placement of cardiac implantable device (pacemaker, ICD, VAD) Heart transplantation (± previous VAD) 	Cefazolin	Vancomycin	Vancomycin plus Cefazolin Allergy: Vancomycin	≤ 24 hours	Delayed sternal closure: Optimal duration is not well defined but should be ≤ 24 hours after closure
Urological					
Hypospadias repair	Cefazolin (Option to limit prophylaxis to proximal hypospadias)	Clindamycin (Option to limit prophylaxis to proximal hypospadias)	Vancomycin plus Cefazolin Allergy: Vancomycin (Option to limit prophylaxis to proximal hypospadias)	Single pre-op dose	
Ureteral reimplantation	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Sacral neuromodulator implantation	Cefazolin plus Gentamicin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	

Aim: To standardize surgical antibiotic prophylaxis.

TABLE 1. RECOMMENDATIONS FOR PERIOPERATIVE ANTIBIOTIC SELECTION

Type of Procedure	Recommended Agent(s)	Severe β -lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
Urological, continued					
Pyeloplasty, open	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Pyeloplasty, robotic	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Nephrectomy	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Vesicostomy	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Ureterostomy	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Ureteroscopy w/wo stone manipulation	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Cystoscopy with urothelial manipulation	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Cystoscopy without urothelial manipulation	None	None	None	N/A	
Ureterocele puncture	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Posterior urethral valves incision	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Circumcision, chordee repair, Orchiopexy, Urethromeatoplasty, Torsion repair	None	None	None	N/A	
Augment cystoplasty discharge with SP-tube	Cefoxitin	Levofloxacin plus Metronidazole	Vancomycin plus Cefoxitin Allergy: Vancomycin plus Levofloxacin plus Metronidazole	24 hours or until intra-op urine culture results are available to allow targeted antimicrobial treatment	
ACE procedure	Cefoxitin	Levofloxacin plus Metronidazole	Vancomycin plus Cefoxitin Allergy: Vancomycin plus Levofloxacin plus Metronidazole	24 hours	
Mitrofanoff procedure	Cefoxitin	Levofloxacin plus Metronidazole	Vancomycin plus Cefoxitin Allergy: Vancomycin plus Levofloxacin plus Metronidazole	24 hours	

Aim: To standardize surgical antibiotic prophylaxis.

Type of Procedure	Recommended Agent(s)	Severe β -lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
Neurosurgical					
Spinal procedures without hardware implantation					
Idiopathic or neuromuscular/ syndromic patients with bowel and bladder control	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	24 hours	
Neuromuscular/syndromic patients without bowel and bladder control	Cefazolin plus Gentamicin	Clindamycin plus Gentamicin	Vancomycin plus Gentamicin	24 hours	
Myelomeningocele repair in patients \leq 72 hours of age	Ampicillin plus Gentamicin	N/A	Vancomycin plus Ampicillin plus Gentamicin	24 hours	
Spinal procedures with hardware implantation					
Halo application, cervical and thoracic fusion	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	24 hours	
Lumbar fusion, insertion of lumbar drain	Cefazolin plus Gentamicin	Clindamycin plus Gentamicin	Vancomycin plus Gentamicin	24 hours	
Cranial procedures					
Cranial procedures without sinus violation	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	24 hours	
Cranial procedures with sinus violation	Ampicillin-sulbactam	Clindamycin plus Gentamicin	Vancomycin plus Ampicillin-sulbactam Allergy: Vancomycin plus Clindamycin plus Gentamicin	24 hours	
Ophthalmic					
All ophthalmic surgeries	Practice varies to include: <ul style="list-style-type: none"> • Topical neomycin– polymyxin B– dexamethasone OR tobramycin- dexamethasone at the end of procedure • Cefazolin (50 mg) by subconjunctival injection or intracameral moxifloxacin (450–600 mcg) at the end of procedure • Erythromycin ointment at the end of procedure 	N/A	N/A	Practice varies to include: <ul style="list-style-type: none"> • Topical neomycin–polymyxin B– dexamethasone OR tobramycin-dexamethasone drops TID x 7 days or BID x 10 days 	

Aim: To standardize surgical antibiotic prophylaxis.

Type of Procedure	Recommended Agent(s)	Severe β -lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
ENT					
Otic/Ear					
Implants (cochlear and other)	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	Single pre-op dose	Post-op amoxicillin-clavulanate x 5 days
Ear cases (clean)	None	None	None	N/A	
Ear cases (clean-contaminated)	None unless active infection	None unless active infection	None unless active infection	N/A	
Tympanoplasty with tube placement Tympanoplasty with skin incision Mastoidectomy/ Tympanomastoidectomy	None unless active infection	None unless active infection	None unless active infection	N/A	
Salivary gland procedures (including removal/ligation)	Ampicillin-sulbactam	Clindamycin	Vancomycin plus Ampicillin-sulbactam Allergy: Vancomycin plus Clindamycin	Continue post-op IV antibiotics x 7 days (combined IV and oral therapy)	
Salivary gland tumor removal	None	None	None	N/A	
Facial					
Facial fractures (maxillary, zygomatic, or mandibular condyle surgery)	None	None	None	N/A	
Facial fractures with concern for sinus involvement	Ampicillin-sulbactam	Clindamycin	Vancomycin plus Ampicillin- sulbactam Allergy: Vancomycin plus Clindamycin	• If no significant disruption, no post-op prophylaxis needed • If significant disruption, continue post-op IV antibiotics x 3–5 days	
Facial fractures with incision through face and orbital fracture	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	Single pre-op dose	
Nasal					
Septoplasty	None	None	None	N/A	
Open septorhinoplasty	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	• If allograft used, no post- operative IV antibiotics needed • If allograft not used, post- operative antibiotics only if splints left in place	If splints in place, post-op cephalexin or clindamycin until removal

Aim: To standardize surgical antibiotic prophylaxis.

Type of Procedure	Recommended Agent(s)	Severe β -lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
ENT, continued					
Sinus					
Sinus surgery	None If cystic fibrosis, antibiotic selection may be directed by pulmonology for appropriate coverage	None If cystic fibrosis, antibiotic selection may be directed by pulmonology for appropriate coverage	None If cystic fibrosis, antibiotic selection may be directed by pulmonology for appropriate coverage	N/A	
Oropharyngeal					
Intra-oral procedures (including mucosal/tongue biopsy), Tonsillectomy	None	None	None	N/A	
Mandibular distraction	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	Continue postop antibiotics until external pins removed for ≤ 7 days (combined IV and oral therapy)	
Facial plastics/cleft lip and palate repair	None	None	None	N/A	
Cervical/Neck					
Neck surgery clean-contaminated	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	Single pre-op dose	
Neck mass/cyst excision	None	None	None	N/A	
Brachial cleft cyst	None unless actively infected	None unless actively infected	None unless actively infected	N/A	
Tracheostomy/tracheotomy	None (continue antibiotics if previously prescribed)	None (continue antibiotics if previously prescribed)	None (continue antibiotics if previously prescribed)	N/A	
Total Thyroidectomy, parathyroidectomy	None	None	None	N/A	
Airway reconstruction	Cefazolin if no <i>Pseudomonas</i> ; If <i>Pseudomonas</i> colonization, Cefepime	Clindamycin if no <i>Pseudomonas</i> ; If <i>Pseudomonas</i> colonization, Clindamycin plus Ciprofloxacin	Vancomycin plus Cefazolin Allergy: Vancomycin	If no MRSA, continue IV antibiotics until drain removed If MRSA, continue IV antibiotics until able to take oral TMP-SMX	If MRSA colonization or infection, TMP-SMX x 3 days before surgery and to complete 14 total days of post-op antibiotics
Pharyngeal flap	None	None	None	N/A	

Aim: To standardize surgical antibiotic prophylaxis.

Type of Procedure	Recommended Agent(s)	Severe β -lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
ENT, continued					
Craniofacial Reconstruction					
Cranioplasty/facial reconstruction	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	72 hours	
Skull base surgery	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	Continue post-op IV antibiotics until packing removed	
Oral and Maxillofacial Surgery					
Palatoplasty with bone grafting	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	24 hours	
Orthognathic surgery	Ampicillin	Clindamycin	Vancomycin plus Ampicillin Allergy: Vancomycin plus Clindamycin	24 hours	Oral antibiotics may be continued upon conclusion of post-operative IV antibiotics to complete a 7 day course
Alloplastic temporomandibular joint (TMJ) replacement	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Clindamycin	48 hours	After completion of IV antibiotics, oral antibiotics will be continued to complete a 7 day course.
Third molar extraction/Dental implants	Ampicillin	Clindamycin	Vancomycin plus Ampicillin Allergy: Vancomycin plus Clindamycin	Single pre-op dose	High risk cardiac patients should follow preoperative antibiotic prophylaxis per American Heart Association (AHA) guidelines. Antibiotics to be continued after surgery if adherence to oral hygiene measures is not feasible (e.g. neurodevelopmental delay or aspiration risk) or if preceding tissue inflammation
Maxillofacial fracture surgery	Ampicillin-sulbactam	Clindamycin	Vancomycin plus Ampicillin- sulbactam Allergy: Vancomycin plus Clindamycin	•If no significant disruption, no post-op prophylaxis needed If significant disruption, continue post-op IV antibiotics □ 3-5 days	Prophylaxis is not recommended in setting of maxillary, zygomatic, or mandibular condyle surgery

Aim: To standardize surgical antibiotic prophylaxis.

Type of Procedure	Recommended Agent(s)	Severe β -lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
Gynecological					
Hysterectomy (supracervical, vaginal, abdominal, laparoscopic, robotic)	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	Screening for bacterial vaginosis in patients undergoing hysterectomy can be considered
Colporrhaphy	Cefazolin	Clindamycin plus Gentamicin	No change	Single pre-op dose	
Laparotomy without entry into bowel or vagina	Consider cefazolin	Consider clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	Decision for antibiotic surg. prophylaxis is based on risk factors (e.g., obesity, diabetes)
Cystoscopy	None	None	None	N/A	Rule out urinary tract infection; treat positive urine culture prior to procedure
Hysterosalpingogram and Chromotubation	None, unless history of PID or abnormal tubes; If history of PID or abnormal tubes, doxycycline 100 mg BID for 5 days starting the night prior to procedure AND Cefazolin pre-operatively	If history of PID or abnormal tubes, Doxycycline plus Clindamycin plus Gentamicin	No change	Single pre-op dose of cefazolin If tubes abnormal at time of procedure, discharge on doxycycline 100 mg BID x 5 days	History of PID or abnormal tubes, doxycycline 100 mg BID x 5 days total
Sonohysterography (saline infusion sonography)	None	None	None	N/A	
Cervical tissue excision procedures (LEEP, biopsy, endocervical curettage)	None	None	None	N/A	
Endometrial biopsy	None	None	None	N/A	
Laparoscopic procedures without entry into bowel or vagina	None	None	None	N/A	
Hysteroscopy (operative or diagnostic)	None	None	None	N/A	
Intrauterine device insertion	None	None	None	N/A	
D&C for non-pregnancy indications	None	None	None	N/A	

Aim: To standardize surgical antibiotic prophylaxis.

Type of Procedure	Recommended Agent(s)	Severe β -lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
Orthopedic Trauma					
Open fractures	See Recommendations for Open Fracture Antibiotic Prophylaxis				
Closed fractures with implantation of internal fixation devices (e.g., nails, screws, plates, wires)	Cefazolin	Clindamycin	Vancomycin plus Cefazolin	≤ 24 hours	
Simple supracondylar humeral fractures pinned percutaneously	None	None	None	N/A	
Plastic Surgery					
Clean with risk factors or clean-contaminated	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	≤ 24 hours	
Vascular					
All	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	≤ 24 hours	
Fetal Surgery					
All	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	≤ 24 hours	
General Surgery					
Thoracic					
Lobectomy, pneumonectomy, lung resection, thoracotomy, video-assisted thoracoscopic surgery	Cefazolin	Clindamycin	Vancomycin plus Cefazolin Allergy: Vancomycin	Single pre-op dose	
Tracheoesophageal fistula (TEF) repair	Cefazolin OR Ampicillin plus Gentamicin (if other maternal/neonatal indications)	N/A	Vancomycin plus Cefazolin	≤ 24 hours	
Congenital diaphragmatic hernia (CDH)	Cefazolin	N/A	Vancomycin plus Cefazolin	<ul style="list-style-type: none"> No patch: Single pre-op dose Patch w/o chest tube: < 24 hrs Patch w/ chest tube: 24–48 hrs 	

Aim: To standardize surgical antibiotic prophylaxis.

Type of Procedure	Recommended Agent(s)	Severe β -lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
General Surgery, continued					
Biliary tract					
Open procedure	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Laparoscopic procedure Elective, low-risk	Cefazolin OR consider no antibiotic prophylaxis	Clindamycin plus Gentamicin OR consider no antibiotic prophylaxis	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin OR consider no antibiotic prophylaxis	Single pre-op dose	
Laparoscopic procedure Elective, high-risk	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Gastroduodenal					
Procedures involving entry into lumen of gastrointestinal tract (e.g., duodenal atresia)	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Gastroschisis	Cefazolin OR Ampicillin plus Gentamicin (if other maternal/neonatal indications)	N/A	Vancomycin plus Cefazolin	\leq 48 hours	<ul style="list-style-type: none"> Antibiotics are recommended from delivery until silo placed or primary closure. No antibiotics needed while silo in place Initiate perioperative coverage at time of final closure until 48 hours postoperatively
Procedures without entry into GI tract for high-risk patients	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Small intestine and colorectal (continues on next page)					
Hernia repair (hernioplasty and herniorrhaphy)	None	None	None	N/A	
Nonobstructed small intestine	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	Single pre-op dose	
Obstructed small intestine	Cefoxitin	Ciprofloxacin plus Metronidazole	Vancomycin plus Cefoxitin Allergy: Vancomycin plus Ciprofloxacin plus Metronidazole	Single pre-op dose	
Stoma revisions and/or closures (small intestine only)	Cefazolin	Clindamycin plus Gentamicin	Vancomycin plus Cefazolin Allergy: Vancomycin plus Gentamicin	< 24 hours	
Stoma revisions and/or closures (small intestine and colon or colostomy)	Cefoxitin	Ciprofloxacin plus Metronidazole	Vancomycin plus Cefoxitin Allergy: Vancomycin plus Ciprofloxacin plus Metronidazole	< 24 hours	

Aim: To standardize surgical antibiotic prophylaxis.

Type of Procedure	Recommended Agent(s)	Severe β -lactam Allergy (Link to Appendix A)	MRSA Colonization OR History of MRSA Infection	Postoperative Duration	Comments
General Surgery, continued					
Small intestine and colorectal, continued					
Colorectal procedures	Cefoxitin	Ciprofloxacin plus Metronidazole	Vancomycin plus Cefoxitin Allergy: Vancomycin plus Ciprofloxacin plus Metronidazole	Single pre-op dose	
Necrotizing enterocolitis (NEC)	See Star Net Clinical Guidelines and Decision Support page for Antibiotic Stewardship Recommendations for NEC in the CVICU and NICU				
Appendectomy					
Uncomplicated (including gangrenous appendicitis)	Ceftriaxone plus Metronidazole	Ciprofloxacin plus Metronidazole	Vancomycin plus Ceftriaxone plus Metronidazole Allergy: Vancomycin plus Ciprofloxacin plus Metronidazole	Single pre-op dose	
Complicated appendicitis or other ruptured colorectal viscus	Ceftriaxone plus Metronidazole	Ciprofloxacin plus Metronidazole	Vancomycin plus Ceftriaxone plus Metronidazole Allergy: Vancomycin plus Ciprofloxacin plus Metronidazole	≤ 24 hours	Appropriate antibiotic treatment should be administered for underlying infection beyond perioperative prophylaxis.

Aim: To standardize surgical antibiotic prophylaxis.

TABLE 2. RECOMMENDATIONS FOR PERIOPERATIVE DOSING OF PROPHYLACTIC ANTIBIOTICS IN NEONATES [POSTMENSTRUAL AGE (PMA) <44 WEEKS]

Antibiotic	Pre-Op Dose	Timing of Pre-Op Dose	Administration	Intra-Op Dose	Post-Op Dose		
Ampicillin	50 mg/kg	Begin within 60 min before incision; If possible, complete 15 min prior to incision	IVP over 3–5 min	50 mg/kg q4h	50 mg/kg q12h		
Cefazolin	30 mg/kg		IVP over 3–5 min	30 mg/kg q4h	PNA 0–7 days: 30 mg/kg q12h PNA ≥ 8 days: 30 mg/kg q8h		
Cefazolin (cardiopulmonary bypass, CPB)	30 mg/kg		IVP over 3–5 min	15 mg/kg at initiation of CPB AND again with weaning off of CPB or at 4 hours (whichever is shorter)	PNA 0–7 days: 30 mg/kg q12h PNA ≥ 8 days: 30 mg/kg q8h		
Cefepime	PNA ≤ 28 days and ≤ 2 kg 30 mg/kg		IV over 30 min	If procedure lasts > 8 hours, redose based on Post-Op dosing interval	PNA ≤ 28 days and ≤ 2 kg 30 mg/kg q12h		
	All others: 50 mg/kg				PNA ≤ 28 days and > 2 kg 50 mg/kg q12h PNA > 28 days 50 mg/kg q8h		
Cefoxitin	30 mg/kg				IVP over 3–5 min	30 mg/kg q2h	30 mg/kg q8h
Gentamicin	4 mg/kg	IV infusion over 20 min with 10 min flush			None	PNA ≤ 7 days and < 1,250 g 4 mg/kg q48h All others 4 mg/kg q24h	
Vancomycin	15 mg/kg	Begin within 120 min before incision; If possible, complete 15 min prior to incision			IV over 60 min	If procedure lasts > 8 hours, redose based on Post-op dosing interval	PMA ≤ 29 weeks
							PNA ≤ 14 days: 15 mg/kg q18h PNA > 14 days: 10-15 mg/kg q12h
			PMA 30–36 weeks				
			PNA ≤ 14 days: 10-15 mg/kg q12h PNA > 14 days: 10-15 mg/kg q8h				
					PMA 37–44 weeks		
					PNA ≤ 14 days: 15 mg/kg q8-12h PNA > 14 days: 10-15 mg/kg q8h		

Abbreviations: PNA = postnatal age

Aim: To standardize surgical antibiotic prophylaxis.

TABLE 3. RECOMMENDATIONS FOR PERIOPERATIVE DOSING OF PROPHYLACTIC ANTIBIOTICS IN PEDIATRIC [POSTMENSTRUAL AGE (PMA) ≥ 44 WEEKS] AND ADULT PATIENTS

Antibiotic	Pre-Op Dose	Timing of Pre-Op Dose	Administration	Intra-Op Dose	Post-Op Dose
Ampicillin	50 mg/kg (max 2000mg)	Begin within 60 min before incision; If possible, complete 15 min prior to incision	IVP over 3–5 min	q2h	q6h
Ampicillin-Sulbactam	50 mg/kg (max 2000 mg) of ampicillin component		IV over 15 min	q2h	q6h
Cefazolin	30 mg/kg (max 2000mg)		IVP over 3–5 min	q4h	q8h
	If ≥ 120 kg: 3000 mg		IVP over 3–5 min	15 mg/kg at initiation of CPB AND again with weaning off of CPB or at 4 hours (whichever is shorter)	30 mg/kg q8h
Cefazolin (cardiopulmonary bypass, CPB)	30 mg/kg (max 2000 mg)				
	If ≥ 120 kg: 3000 mg		IV over 30 min	q4h	q8h
Cefepime	50 mg/kg		IVP over 3–5 min	q2h	q6h
Cefoxitin	40 mg/kg (max 2000 mg)		IV over 30 min	No redose	q24
Ceftriaxone	50 mg/kg (max 2000mg)	Begin within 120 min before incision; If possible, complete 15 min prior to incision	IV over 60 min	If procedure lasts > 12 hours, redose based on Post-op dosing interval	q12h
Ciprofloxacin	10 mg/kg (max 400 mg)				
Clindamycin	10 mg/kg (max 900 mg)	Begin within 60 min before incision; If possible, complete 15 min prior to incision	IV infusion at ≤ 30 mg/min	If procedure lasts > 6 hours, redose based on Post-op dosing interval	q8h
Gentamicin	2.5 mg/kg (use adjusted body weight if ≥ 95% percentile BMI for age and sex)		IV infusion over 20 min with 10 min flush	If procedure lasts > 8 hours, redose based on Post-op dosing interval	q8h
Levofloxacin	10 mg/kg (max 500 mg)	Begin within 120 min before incision; If possible, complete 15 min prior to incision	IV over 60 min	N/A	q12h (if 6 months to < 5 years old)
					q24h (if ≥ 5 years old)
Metronidazole	10 mg/kg (max 500 mg)	Begin within 60 min before incision; If possible, complete 15 min prior to incision	IV over 30–60 min	If procedure lasts > 8 hours, redose based on Post-op dosing interval	q8h
Metronidazole (appendicitis)	30 mg/kg (max 1500 mg)		IV over 30–60 min	N/A	q24h
Vancomycin	15 mg/kg (max 1500 mg)	Begin within 120 min before incision	IV over 60 min (if dose is ≤ 1000 mg) or over 90 min (if dose is > 1000–1500 mg)	If procedure lasts > 8 hours, redose based on Post-op dosing interval	q8h

Aim: To standardize surgical antibiotic prophylaxis.

REFERENCES

Bratzler DW et al. *Am J Health-Syst Pharm.* 2013;70: 195-283

Berrios-Torres SI et al. *JAMA Surg.* 2017;152(8): 784-791

Red Book 2018-2021: pp 1031-1043

2020 Nelson's Pediatric Antimicrobial Therapy, 26th Edition

Soriano A et al. *Clin Infect Dis.* 2008;46: 1009-14

Bull AL et al. *Ann Surg.* 2012;256: 1089-92

Branch-Elliman W et al. *JAMA Surg.* 2019;154: 590-598

De Cock PA et al. *Antimicrob Chemother.* 2017;72: 791-800

He K et al. *JAMA Surg.* 2022. Epub ahead of print. PMID: 36260310

Ingrande J et al. *Anesth Analg.* 2019;128: 935-43

Kusne S et al. *J Heart Lung Transplant.* 2017;36: 1137-1153

Nienaber JJ et al. *Clin Infect Dis.* 2013;57: 1438-48

Jaworski R et al. *Surg Infect (Larchmt).* 2019;20: 253-260

Aburjania N et al. *ASAIO J.* 2018;64: 735-740

Chua ME et al. *J Pediatr Urol.* 2019;15: 138-148

Lightner DJ et al. *J Urol.* 2020;203: 351-356

Alford EN et al. *J Neurosurg Pediatr.* 2019;30: 1-10

Patel PN et al. *Otolaryngol Head Neck Surg.* 2018;158: 783-800

Vander Poorten V et al. *Adv Ther.* 2020;37: 1360-1380

American College of Obstetricians and Gynecologists. *Obstet Gynecol.* 2018;131:e172-e189

Pittaway DE et al. *Am J Obstet Gynecol.* 1983;147: 623-626

Ravikumar C et al. *Pediatr Infect Dis J.* 2020;39: 1116-1120

Laituri C, Arnold MA *Semin Pediatr Surg.* 2019;28: 53-56

Murthy K et al. *J Pediatr.* 2018;203: 101-107

Pacifici GM Pharmaceuticals (Basel). 2010;3: 2568-2591

Shoji K et al. *Antimicrob Agents Chemother.* 2016;60: 2150-6

Rybak MJ et al. *Am J Health-Syst Pharm.* 2020;77: 835-864

Workgroup

Prepared by Christina Koutsari, PharmD PhD BCPS BCIDP, and Bill Pomputius on 11/02/20

Approved by Cardiovascular Surgery (12/02/20), Urology (12/04/20), Neurosurgery (12/17/20), Ophthalmology (11/18/20), ENT (12/04/20), Gynecology (11/30/20), Orthopedic Trauma (11/28/20), Fetal Surgery (12/18/20), General Surgery (12/04/20), Infectious Disease (12/09/20) and the Antimicrobial Stewardship Committee (12/09/20)

Updated by Mary Ullman, PharmD and Bill Pomputius with guidance from Oral and Maxillofacial Surgery and ENT on 7/31/24

Appendix A

Aim: To standardize surgical antibiotic prophylaxis.

Patient with PENICILLIN allergy label

Discuss with Infectious Disease if allergy label to: carbapenem, aztreonam, or multiple classes of beta-lactams (e.g. penicillin and cephalosporin).

- Evaluate reported allergy and severity (**Table 4**) by obtaining information on:
 - Previous evaluation by an allergist for penicillin allergy.
 - Name of penicillin(s) that allergy label applies to.
 - Reaction details (e.g. see **page 18** for rash type examples).
 - Timing/onset of reaction: Immediate/acute (≤ 24 hrs of penicillin dosing), delayed (> 24 hrs of penicillin dosing).
 - Treatment of reaction: None/antibiotic continued, antibiotic discontinued, antihistamines, steroids, epinephrine, hospitalization/ED.
 - Tolerance of culprit penicillin and other beta-lactams before and after course that caused the reaction.
- Update EMR with information above.

Severe Type II-IV reactions(delayed)

- Stevens-Johnson syndrome (SJS).
- Toxic epidermal necrolysis (TEN).
- Drug reaction with eosinophilia and systemic symptoms (DRESS).
- Acute generalized exanthematous pustulosis (AGEP).
- Generalized bullous fixed drug eruption (GBFDE).
- Linear IgA bullous dermatosis.
- **Severe** maculopapular rash.
- Drug-induced autoimmune disease (bullous pemphigoid, pemphigus vulgaris, drug-induced lupus).
- Serum sickness.
- Blood disorders (hemolytic anemia, agranulocytosis, thrombocytopenia).
- Drug-induced liver injury, nephritis, pneumonitis, meningitis, pancreatitis, vasculitis.
- Drug fever.

Use NON beta-lactam antibiotics appropriate to procedure (see **Table 1**, “**Severe β-lactam Allergy**” column).

Severe Type I reactions(immediate)

- Anaphylaxis (**Table 5**).
- **Skin:** Acute urticaria (hives), angioedema, flushing/redness.
- **CV:** Hypotension, syncope.
- **GI:** Repetitive vomiting, abdominal cramping.
- **MSK:** Hypotonia.
- **Resp:** Dyspnea, wheezing, hypoxia, repetitive coughing, stridor, aphonia, dysphonia.

Non-severe reactions

- **Mild/moderate** maculopapular rash.
- Isolated pruritus without rash.
- **Delayed** urticaria* with pruritus and without other systemic symptoms.
- Patient denies allergy but is on record.

Can use cefazolin, cefoxitin, or ceftriaxone.

Reactions inconsistent with allergy

- Isolated intolerances: diarrhea, nausea, vomiting (not repetitive), mild abdominal pain, headache, fatigue, vaginitis.
- Family history of allergy to penicillin.
- Patient tolerated culprit penicillin after allergy label.

Can use cefazolin, cefoxitin, ceftriaxone, or ampicillin-sulbactam.

***Delayed urticaria:** Onset at >24 hours of penicillin dosing, or after 2 doses, whichever is longer.

†**Classification of maculopapular rash:**
Severe: Widespread rash that may become confluent and develop into erythroderma; >1-wk duration, with systemic involvement (e.g., fever, eosinophilia); rarely, with minimal vesicles or pustules.
Moderate: More or less widespread rash; >1-wk duration, without systemic involvement.
Mild: More or less widespread rash; <1-wk duration, without systemic involvement.

Appendix A

Aim: To standardize surgical antibiotic prophylaxis.

Patient with CEPHALOSPORIN allergy label

Discuss with Infectious Disease if allergy label to: carbapenem, aztreonam, or multiple classes of beta-lactams (e.g. penicillin and cephalosporin).

- Evaluate reported allergy and severity (**Table 4**) by obtaining information on:
 - Previous evaluation by an allergist for penicillin allergy.
 - Name of cephalosporin(s) that allergy label applies to.
 - Reaction details (e.g. see **page 18** for rash type examples).
 - Timing/onset of reaction: Immediate/acute (≤ 24 hrs of cephalosporin dosing), delayed (> 24 hrs of cephalosporin dosing).
 - Treatment of reaction: None/antibiotic continued, antibiotic discontinued, antihistamines, steroids, epinephrine, hospitalization/ED.
 - Tolerance of culprit cephalosporin and other beta-lactams before and after course that caused the reaction.
- Update EMR with information above.

Severe Type II-IV reactions (delayed)

- Stevens-Johnson syndrome (SJS).
- Toxic epidermal necrolysis (TEN).
- Drug reaction with eosinophilia and systemic symptoms (DRESS).
- Acute generalized exanthematous pustulosis (AGEP).
- Generalized bullous fixed drug eruption (GBFDE).
- Linear IgA bullous dermatosis.
- Severe**† maculopapular rash.
- Drug-induced autoimmune disease (bullous pemphigoid, pemphigus vulgaris, drug-induced lupus).
- Serum sickness.
- Blood disorders (hemolytic anemia, agranulocytosis, thrombocytopenia).
- Drug-induced liver injury, nephritis, pneumonitis, meningitis, pancreatitis, vasculitis.
- Drug fever.

Severe Type I reactions (immediate)

- Anaphylaxis (**Table 5**)
- Skin:** **Acute** urticaria (hives), angioedema, flushing/redness.
- CV:** Hypotension, syncope.
- GI:** Repetitive vomiting, abdominal cramping.
- MSK:** Hypotonia.
- Resp:** Dyspnea, wheezing, hypoxia, repetitive coughing, stridor, aphonia, dysphonia.

Non-severe reactions

- Mild/moderate**† maculopapular rash.
- Isolated pruritus without rash.
- Delayed** urticaria* with pruritus and without other systemic symptoms.
- Patient denies allergy but is on record.

Use table below to assess if cefazolin, cefoxitin, ceftriaxone can be used based on cephalosporin allergy label:
 -If **green box**, can use.
 -If **red box**, use NON beta-lactam antibiotic.

Reactions inconsistent with allergy

- Isolated intolerances: diarrhea, nausea, vomiting (not repetitive), mild abdominal pain, headache, fatigue, vaginitis.
- Family history of allergy to penicillin.
- Patient tolerated culprit penicillin after allergy label.

Can use cefazolin, cefoxitin, ceftriaxone, or ampicillin-sulbactam.

Use NON beta-lactam antibiotics appropriate to procedure (see **Table 1**, "Severe β -lactam Allergy" column).

*Delayed urticaria: See definition on page 15.

†Classification of maculopapular rash: See page 15.

Reported allergy to:	1 st			2 nd			3 rd			4 th	5 th					
	Cefadroxil	Cephalexin	Cefazolin	Cefoxitin	Cefuroxime	Cefprozil	Cefdinir	Cefixime	Ceftriaxone	Cefotaxime	Cefpodoxime	Ceftazidime	Cefepime	Ceftaroline	Ceftolozane	Cefiderocol
Cefazolin	Green	Green	Red	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Cefoxitin	Green	Green	Green	Red	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green	Green
Ceftriaxone	Green	Green	Green	Green	Red	Green	Green	Red	Red	Red	Red	Red	Red	Red	Red	Green

1st, 2nd, 3rd, etc. refer to generation of cephalosporins.

Appendix A

Aim: To standardize surgical antibiotic prophylaxis.

Table 4. Immune-Mediated Antibiotic Hypersensitivity Reactions

Type	Description	Pathogenesis	Onset of Reaction	Typical Clinical Findings
I (Immediate)	IgE-mediated hypersensitivity	Antibiotic-specific IgE binds to mast cells and basophils. Subsequent antibiotic exposure leads to mast cell and basophil degranulation	Minutes to an hour (can also be considered within 6 hours of exposure)	Anaphylaxis, urticaria (hives), angioedema, repetitive vomiting, SOB, wheezing, chest pain, palpitations, syncope, cardiac arrest
II (Delayed)	IgG-mediated hypersensitivity	Antibiotic binds to WBC, RBC, or platelet and acts as antigen leading to antibody mediated cell destruction	Days to weeks	Hemolytic anemia, thrombocytopenia, neutropenia
III (Delayed)	Immune-complex mediated hypersensitivity	Antibiotic and IgG/IgM bind to form immune complex activate complement	Days to weeks	Serum sickness (fever, urticaria, arthralgia, lymphadenopathy), drug fever, vasculitis
IV (Delayed)	Cell-mediated hypersensitivity	Antigen specific T-cell activation	Days to weeks	Pustules, vesicles, desquamation, exfoliative exanthema, contact dermatitis, maculopapular rash, DRESS, SJS, TEN, AGEP, acute interstitial nephritis, drug-induced liver injury,

AGEP: acute generalized exanthematous pustulosis. **DRESS:** drug rash with eosinophilia and systemic symptoms. **RBC:** red blood cell. **WBC:** white blood cell. **SJS:** Stevens-Johnson Syndrome. **SOB:** shortness of breath. **TEN:** toxic epidermal necrolysis.

Table 5. Anaphylaxis is highly likely when any one of the following 2 criteria are fulfilled:

- 1. Acute onset* of an illness with involvement of the skin, mucosal tissue, or both (e.g. generalized hives, pruritus or flushing, swollen lips-tongue-uvula) AND ≥ 1 of the following:**
 - a. Respiratory compromise (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow (PEF), hypoxemia)
 - b. Reduced blood pressure** or associated symptoms of end-organ dysfunction (e.g. hypotonia [collapse], syncope, incontinence)
 - c. Severe gastrointestinal symptoms (e.g. severe crampy abdominal pain, repetitive vomiting)
- 2. Acute onset of hypotension* or bronchospasm or laryngeal involvement (stridor, vocal changes, odynophagia) even in the absence of typical skin involvement**

*Minutes to several hours from exposure. Most immediate reactions occur within the 1st hour following drug administration.

**Hypotension defined as systolic blood pressure (mm Hg):

- < 12 months of age: < 70
- 1-10 years of age: < 70 + (2 × age in years)
- > 10 years of age: < 90.

Appendix A

Aim: To standardize surgical antibiotic prophylaxis.

Examples of Rash Types

<p>Macular papular rash</p> 		<ul style="list-style-type: none"> • Typically non-severe skin reaction • Tiny red dots covering a large area of the body, may feel rough to the touch. • Appears after 2—3 days (or later) of antibiotic administration (delayed reaction). • Can be treated through, does not contraindicate future antibiotic use. • May not recur with future drug administration.
<p>Urticaria (hives)</p> 		<ul style="list-style-type: none"> • Itchy, red bumps with white centers (look like new mosquito bites). • Typically appear within 6 hours of antibiotic administration (but can be a delayed reaction too). • Bumps disappear after a few hours and new ones may appear.
<p>Severe skin drug reaction (exfoliating dermatitis)</p> 		<ul style="list-style-type: none"> • Skin peeling or blistering with mucosal (eyes, mouth, genital) involvement • Develops after several days of antibiotics. • Examples: Stevens-Johnson syndrome, Toxic Epidermal necrolysis (TEN) • Requires hospitalization
<p>Erythema multiforme</p> 		<ul style="list-style-type: none"> • Rings containing a "bull's-eye" • Appears after 2-3 days of antibiotic administration (delayed reaction)

Images used with permission from the following references:

- [penicillin-allergy-algorithm-with-pictures.pdf \(hopkinsmedicine.org\)](#)
- Atlas of Dermatological Conditions in Populations of African Ancestry. CMYA Donkor, J Aryee-Boi, IR Osazuwa, FK Afflu, AF Alexis. Springer Cham 2021

Appendix A**Aim:** To standardize surgical antibiotic prophylaxis.**REFERENCES**

- Bhathal S et al. *Surgery*. 2022;172(6): 1598-1603.
- Blumenthal KG et al. *Clin Infect Dis*. 2018;66(3): 329-336.
- Cantona B A et al. *World Allergy Organ J*. 2020;13(10): 100472.
- Caubet JC et al. *J Allergy Clin Immunol Pract*. 2011;127(1): 218-222.
- Khan DA et al. *J Allergy Clin Immunol*. 2022;150(6):1333-1393.
- Kuruvilla M et al. *J Allergy Clin Immunol Pract*. 2020;8(4): 1316-1322.
- Lessard S et al. *Am J Health Syst Pharm*. 2023;80(8): 532-536.
- Maker JH et al. *Pharmacy (Basel)*. 2019;7(3): 122.
- Zagursky RJ et al. *J AllergyClin Immunol Pract* 2018;6(1): 72-81.

Work group

Ullman, Koutsari, Pomputius, Sheng (Immunology), Previously Chase (Allergy)